Progression to AML according to the XPD SNP (Lys751Gln) and category of exposure to cytoreductive agents: observed frequencies and ORs derived from the regression model
| . | Observed frequency . | OR (95% CI) . | |||
|---|---|---|---|---|---|
| Global (n = 335)* . | XPD AA/AC (n = 292)† . | XPD CC (n = 41)‡ . | XPD AA/AC . | XPD CC . | |
| No exposure | 1/61 (1.6%) | 0/48 (0%) | 1/12 (8%) | 1.0 | 4 (2.5-10) |
| HU only | 40/204 (20%) | 31/183 (17%) | 8/20 (40%) | 3.5 (2-5.5) | 17 (7-44) |
| Other agents alone or in combination | 23/70 (33%) | 16/61 (26%) | 7/9 (78%) | 12 (4-39) | 61 (13-286) |
| Total | 64/335 (19%) | 47/292 (16%) | 16/41 (39%) | ||
| . | Observed frequency . | OR (95% CI) . | |||
|---|---|---|---|---|---|
| Global (n = 335)* . | XPD AA/AC (n = 292)† . | XPD CC (n = 41)‡ . | XPD AA/AC . | XPD CC . | |
| No exposure | 1/61 (1.6%) | 0/48 (0%) | 1/12 (8%) | 1.0 | 4 (2.5-10) |
| HU only | 40/204 (20%) | 31/183 (17%) | 8/20 (40%) | 3.5 (2-5.5) | 17 (7-44) |
| Other agents alone or in combination | 23/70 (33%) | 16/61 (26%) | 7/9 (78%) | 12 (4-39) | 61 (13-286) |
| Total | 64/335 (19%) | 47/292 (16%) | 16/41 (39%) | ||